Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial
Open Access
- 25 March 2024
- journal article
- research article
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 25 (1) , 1-13
Abstract
Background: The objective of this analysis was to gain new insights into the patient characteristics and other factors associated with lasmiditan usage and clinical outcomes under conditions resembling the real-world setting. Methods: This was a post hoc analysis of data from the 12-month, open-label extension (OLE) of the phase 3, double-blind, randomized, controlled CENTURION trial, which examined the efficacy and safety of lasmiditan as acute treatment across four migraine attacks. Patients completing the main study who treated ≥ 3 attacks could continue in the OLE. The initial lasmiditan dose was 100 mg, with dose adjustments to 50 mg or 200 mg allowed at the investigator’s discretion. Patient and clinical characteristics were summarized by dosing pattern and completion status. Safety was assessed based on adverse event (AE) frequency by number of doses. Results: In total, 445 patients treated ≥ 1 migraine attacks with lasmiditan during the OLE, 321 of whom (72.1%) completed the study. Forty-seven percent of patients remained on the 100-mg initial dose during the OLE whereas 20.2% used both 100 mg and 50 mg, 30.6% used both 100 mg and 200 mg, and 6 (1.3%) used multiple dose levels. All dosing patterns were associated with clinical and patient-reported improvement; however, the 100-mg group had the highest proportion of patients reporting improvement in the Patient Global Impression of Change – Migraine Headache Condition (56.5% vs 33.4%–52.2%). In comparison, all three groups that made dose adjustments had higher rates of completion compared to the 100-mg group (72.1%–83.3% vs 68.9%). The frequency of AEs decreased with continued use of lasmiditan. Concomitant triptans and lasmiditan use did not increase AE frequency. Conclusions: Based on high persistence and patient satisfaction rates, the 100-mg dose appears optimal for most patients. For those who adjusted dose levels, dose adjustments appeared beneficial to improve efficacy or tolerability, retaining patients on treatment. Collectively, the data suggest that patients who experienced efficacy continued to use lasmiditan regardless of the occurrence or frequency of AEs, and continued use appeared associated with fewer AEs. Trial registration: European Union Drug Regulating Authorities Clinical Trials Database (EudraCT): 2018–001661-17; ClinicalTrials.gov: NCT03670810; registration date: September 12, 2018. GraphicalKeywords
Funding Information
- Eli Lilly Japan K.K.
- Daiichi Sankyo Company, Limited
- Eli Lilly and Company
This publication has 24 references indexed in Scilit:
- Emerging experimental drugs in clinical trials for migraine: observations and key talking pointsExpert Opinion on Investigational Drugs, 2023
- Phase 2 randomized placebo‐controlled study of lasmiditan for the acute treatment of migraine in Japanese patientsHeadache: The Journal of Head and Face Pain, 2021
- Acute Migraine: Can the New Drugs Clinically Outpace?SN Comprehensive Clinical Medicine, 2020
- Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)Cephalalgia, 2019
- Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraineBrain, 2019
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd editionCephalalgia, 2018
- Optimal balance of efficacy and tolerability of oral triptans and telcagepant: a review and a clinical commentThe Journal of Headache and Pain, 2011
- Clinical Utility of an Instrument Assessing Migraine Disability: The Migraine Disability Assessment (MIDAS) QuestionnaireHeadache: The Journal of Head and Face Pain, 2001
- Validity and Reliability of the Migraine‐Specific Quality of Life Questionnaire (MSQ Version 2.1)Headache: The Journal of Head and Face Pain, 2000
- ECDEU Assessment Manual1976